Evidence map›Paper›PMID 34815551›Full record

ReviewInternational journal of impotence research2022

Current use of testosterone therapy in LGBTQ populations.

A N Tijerina, A V Srivastava, V R Patel, E C Osterberg

Abstract readReview
PubMed Publisher
In one paragraph

Review in International journal of impotence research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Advancements in the evaluation and treatment for Testosterone Deficiency.International journal of impotence research · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

A N TijerinaUniversity of Texas Dell Medical School, Austin, TX, 78712, USA. adan.tijerina@utexas.edu.ORCID http://orcid.org/0000-0001-6647-5525
A V SrivastavaUniversity of Texas Dell Medical School, Austin, TX, 78712, USA.ORCID http://orcid.org/0000-0002-6169-8209
V R PatelUniversity of Texas Dell Medical School, Austin, TX, 78712, USA.ORCID http://orcid.org/0000-0001-6447-7412
E C OsterbergUniversity of Texas Dell Medical School, Austin, TX, 78712, USA.
The University of Texas at Austin · USSeton Healthcare Family · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Testosterone therapy (TT) is a type of gender-affirming hormone therapy (GAHT) in lesbian, gay, bisexual, transgender, and genderqueer (LGBTQ) populations for gender dysphoria (GD), body uneasiness, and sexual dysfunction. The physical and physiological effects of TT vary widely depending on the dosing regimen and duration of treatment. An individualized approach prioritizing patient-specific desired effects in the context of pre-existing characteristics and health history is strongly recommended. Although TT is an effective treatment for many patients, there has been an increase in the illegitimate acquisition of TT in recent years. Non-judicious prescribing and lack of physician surveillance increases the risk of unintended side effects and potential serious health consequences.

Indexed as

Sexual and Gender MinoritiesTestosteroneBisexualityFemaleGender IdentityHumansSexual BehaviorTestosterone

Identifiers

PMID34815551
OpenAlexW3215880991

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.